MedWatch

Orphazyme expects to lay off 100 employees this year

At the end of July, Orphazyme completed its restructuring program, and according to the biotech company, it expects to have around 70 full-time employees at the end of the year. At the end of the first half-year, 180 people were employed.

Photo: Orphazyme/PR

It is no secret that Orphazyme has been forced to cut down its number of staff considerably after the FDA rejected the biotech company's key candidate arimoclomal as a treatment for metabolic disease Niemann-Pick type C, NPC.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs